Accessibility Menu
Elicio Therapeutics logo

Elicio Therapeutics(NASDAQ) ELTX

Current Price$3.12
Market Cap$73.22MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2023)-83%
5 Year-97%
1 Year-67%
1 Month-25%
Elicio Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 3.122026-07-22
Elicio Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+2.63%USD 3.042026-07-15
1 month-24.64%USD 4.142026-06-22
3 month-73.67%USD 11.852026-04-23
Year to date-60.8%USD 7.962025-12-31
1 year-66.52%USD 9.322025-07-22
3 year-68.64%USD 9.952023-07-21
5 year-97.1%USD 107.502021-07-23
Since inception-83.03%USD 18.152023-06-02

Elicio Therapeutics Financials at a Glance

Market Cap

$73.22MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$40.19M

EPS (TTM)

-$2.34

P/E Ratio

-1.33

Dividend

$0.00

Beta (Volatility)

0.63 (Low)

Price

$3.12

Volume

354,280

Open

$3.08

Previous Close

$3.12

Daily Range

$2.96 - $3.18

52-Week Range

$2.66 - $16.00

Estimated Earnings Date

Aug 6, 2026

ELTX News

Foolcom-Featured.png

Elicio (ELTX) Q2 Loss Beats Estimates

Motley Fool Markets TeamAug 7, 2025

ELTX: Motley Fool Moneyball Superscore

46

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Elicio Therapeutics

Elicio helps doctors treat patients with cancer. It makes vaccines that teach immune cells to kill tumors. These treatments target common genetic changes in cancer.

What Is Elicio Building?

  • ELI-002 7P: A vaccine candidate designed to treat pancreatic cancer by targeting seven common genetic mutations.
  • AMP Technology: A platform that sends medicine directly to lymph nodes to train the immune system.
  • ELI-007 and ELI-008: Preclinical vaccines targeting specific genetic changes linked to a variety of cancer types.
  • ELI-012: A therapy used with other treatments to attack tumors with specific genetic drivers.

Recent Strategic Moves

  • Converted a $20 million debt balance into common stock for GKCC, LLC in March 2025.
  • Secured a $10 million loan agreement in June 2025 with GKCC, LLC to support research operations.
  • Raised $9.2 million in January 2025 through a direct stock sale to institutional investors.
  • Terminated a share sale program with JonesTrading in March 2026 and began a new $100 million program.
  • Maintains a license agreement with the Massachusetts Institute of Technology for intellectual property rights to its core technology.

Training the Immune System

Elicio focuses on "off-the-shelf" treatments that patients can receive immediately without waiting for custom manufacturing. Its technology trains the body's immune command centers, called lymph nodes, to recognize and attack tumor cells.

Measuring the Progress

  • Cash and equivalents stood at $14.9 million on March 31, 2026, down from $18.6 million at the end of 2025.
  • Net loss reached $11.8 million for the first quarter of 2026, worsening 5.5% from the previous year.
  • Operating loss narrowed to $10.6 million in Q1 2026, an improvement of 1.2% over Q1 2025.
  • Research and development spending was $6.8 million in Q1 2026, down 13% from the same period of 2025.
  • General and administrative costs rose 30% to $3.8 million in Q1 2026, up from $3 million in Q1 2025.

The Elicio Evolution

Elicio has transitioned from an early-stage research firm to a clinical-stage biotechnology company testing its primary cancer vaccine. It relies on strategic funding and partnerships to advance its pipeline through human trials toward potential regulatory review.

AI Generated • May 15, 2026

Industry

Biotechnology

Sector

Health Care

Employees

33

CEO

Robert T. Connelly

Website

www.elicio.com

Headquarters

Boston, MA 02210, US

ELTX Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-2748.16%

Return on Capital

-233.55%

Return on Assets

-177.11%

Earnings Yield

-75.19%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$73.22MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

23.47M

Volume

354.28K

Avg. Volume

1.68M

Financials (TTM)

Gross Profit

-$289.00K

Operating Income

-$37.58M

EBITDA

-$37.68M

Operating Cash Flow

-$38.48M

Capital Expenditure

-$16.00K

Free Cash Flow

-$38.49M

Cash & ST Invst.

$14.95M

Total Debt

$14.34M

Elicio Therapeutics Performance Analysis

Elicio Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Elicio Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Elicio Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -892.664520.1%
20232023-12-31USD -6.96-99.2%
20242024-12-31USD -4.25-38.9%
20252025-12-31USD -2.58-39.2%
Elicio Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3024.1%
Q32025-09-309.1%
Q42025-12-3125.0%
Q12026-03-31-44.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$289.00K

-4.0%

Gross Margin

0.00%

N/A

Market Cap

$73.22MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.22M

N/A

Employees

33

N/A

Net Income

-$11.82M

-5.5%

EBITDA

-$11.13M

-3.5%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$14.95M

-18.5%

Total Debt

$14.34M

+147.6%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$13.30M

+173.3%

Short Term Debt

$1.04M

+12.5%

Return on Assets

-1.77%

N/A

Return on Invested Capital

-2.43%

N/A

Free Cash Flow

-$11.65M

-15.1%

Operating Cash Flow

-$11.65M

-15.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SAVACassava Sciences, Inc.
$1.32+2.33%
CRDFCardiff Oncology, Inc.
$0.86+2.38%
RANIRani Therapeutics Holdings, Inc.
$0.90+29.77%
MISTMilestone Pharmaceuticals Inc.
$1.19-3.25%

Trending Stocks

Symbol / CompanyPricePrice Chg
TAT&T
$23.04+0.04%
ONDSOndas
$8.00+0.04%
AALAmerican Airlines Group
$14.79-0.03%
PATHUiPath
$10.70-0.11%

Questions About ELTX

What is the current price of Elicio Therapeutics?

Elicio Therapeutics is trading at $3.12 per share.

What is the 52-week range for Elicio Therapeutics?

Over the past 52 weeks, Elicio Therapeutics has traded between $2.66 and $16.00.

How much debt does Elicio Therapeutics have?

As of the most recent reporting period, Elicio Therapeutics reported total debt of $14.34M.

How much cash does Elicio Therapeutics have on hand?

Elicio Therapeutics reported $14.95M in cash and cash equivalents in its most recent financial results.

What is Elicio Therapeutics’s dividend yield?

Elicio Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services